The FDA has approved Eisai‘s Halaven (eribulin mesylate) Injection for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. “Many women with metastatic breast cancer see their disease progress after receiving multiple therapies,” said Linda Vahdat, M.D., Professor of Medicine, Division of Hematology & Medical Oncology at the Iris Cantor Women’s Health Center at New York-Pr...